Mazdutide
Mazdutide (IBI362 / LY3305677)
Developed originally by Eli Lilly and advanced by Innovent Biologics, Mazdutide (IBI362) functions as a dual GLP-1 and glucagon receptor agonist. Think of it as a synthetic, long-acting version of oxyntomodulin, a naturally occurring hormone that kills appetite while actively burning stored fat. The clinical data out of China right now is staggering, especially regarding its ability to aggressively clear out liver fat while matching or beating the weight loss seen with standard single-agonist drugs.
Buy Mazdutide at Peptide PalacePurity
99%+
Molecular Weight
Approx. 4500 g/mol
Administration
Subcutaneous injection
Storage
Store lyophilized powder at -20°C for long-term preservation
Mechanism of Action
We are looking at a two-pronged metabolic assault here. Mazdutide binds the GLP-1 receptor to delay gastric emptying and signal the brain that you are full. Second, and where it separates itself from pure GLP-1s, it activates the glucagon receptor (GCGR). GCGR agonism actively drives lipolysis, increases energy expenditure, and forces the liver to burn through bound triglycerides. You get the appetite suppression of an incretin combined with a direct metabolic uncoupling effect.
Sequence:
Oxyntomodulin analog with a C20 fatty diacid chain attached via a hydrophilic spacer Research Areas
- Obesity and metabolic syndrome
- Non-alcoholic fatty liver disease (NAFLD/MASLD)
- Type 2 diabetes glycemic control
- Lipid metabolism and hyperlipidemia
- Energy expenditure modulation
Potential Benefits
- Aggressive reduction in total body weight
- Massive clearance of hepatic fat
- Significant appetite suppression
- Increased basal metabolic rate via GCGR
- Improved lipid panels and triglyceride clearance
Research Dosing Guidelines
For research purposes only. Not for human consumption.
Typical Dose
1.0 - 9.0 mg
Frequency
Once weekly
Duration
16-24 weeks
Administration
Subcutaneous injection
For research purposes only. Most protocols start low at 1.0mg weekly to assess gastrointestinal tolerance before titrating up every 4 weeks. The 9mg dose is where the extreme 18%+ weight loss occurs in trials, but the glucagon receptor agonism means researchers consistently observe a higher resting heart rate at that peak dose.
Reconstitution Calculator
U-100 Insulin Syringe
0.0 units
2500 mcg/ml
0.0004 ml
0.0 IU
5000
For research and educational purposes only. Always follow proper reconstitution and sterile handling protocols.
Next-Generation Weight Loss Peptides: Where Mazdutide Fits
The incretin/metabolic peptide landscape is evolving rapidly. Here is how mazdutide compares to the other major players in the obesity pipeline.
Metabolic Peptide Pipeline
| Peptide | Targets | Peak Weight Loss | Unique Feature |
|---|---|---|---|
| Semaglutide | GLP-1 | ~15% | Longest safety track record |
| Tirzepatide | GLP-1 + GIP | ~22% | Dual incretin agonism |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24% | Triple agonism with increased REE |
| Mazdutide | GLP-1 + Glucagon | ~18% | Aggressive liver fat clearance |
| CagriSema | GLP-1 + Amylin | ~15-17% | Plateau-breaking dual pathway |
Mazdutide's glucagon receptor activity gives it a specific edge in hepatic fat clearance — liver fat reductions exceed what pure GLP-1 agonists achieve. This makes it particularly relevant for NAFLD/MASLD research where liver outcomes are the primary endpoint.
Potential Side Effects
- Nausea and vomiting (heavily dose-dependent)
- Diarrhea or constipation
- Elevated resting heart rate
- Lean tissue loss if mechanical tension is absent
Storage Requirements
Store lyophilized powder at -20°C for long-term preservation. Keep reconstituted vials refrigerated at 2-8°C and use within 28 days.
Research References
- [1]Efficacy and safety of mazdutide in Chinese adults with overweight or obesity (Lancet Diabetes Endocrinol, 2021) (2021)Strong Evidence Population: Chinese adults with BMI ≥28 or ≥24 with comorbidities (n=187)
Mazdutide generated dose-dependent weight loss up to an average of 18.6% at the highest 9mg dose over 24 weeks.
Limitations: Chinese population only; generalizability to other ethnicities uncertain
- [2]Mazdutide in Chinese adults with type 2 diabetes: a randomized, double-blind, placebo-controlled Phase 2 trial (Diabetes Care, 2022) (2022)Strong Evidence Population: Chinese adults with T2D inadequately controlled on metformin (n=150)
The dual agonist significantly lowered HbA1c and body weight while drastically reducing liver fat content compared to placebo.
Limitations: Single-ethnicity population; 16-week duration; long-term CV outcomes unknown
- [3]Effect of IBI362 on hepatic fat content and metabolic parameters in NAFLD models (Metabolism, 2023) (2023)Emerging Evidence Population: Diet-induced obese mice with hepatic steatosis
Glucagon receptor agonism in Mazdutide directly drove massive clearance of hepatic triglycerides beyond what GLP-1 alone achieves.
Limitations: Animal model; human liver fat clearance kinetics may differ
Frequently Asked Questions
What is Mazdutide?
Mazdutide (IBI362) is a synthetic dual-agonist peptide originally developed by Eli Lilly that targets both the GLP-1 and glucagon receptors. It mimics the natural hormone oxyntomodulin to suppress appetite while simultaneously increasing energy expenditure and fat burning.
What are the potential research benefits of Mazdutide?
Clinical trials demonstrate aggressive total body weight reduction, often matching or exceeding standard GLP-1 therapies. Because of the added glucagon receptor activity, it also shows massive efficacy in clearing liver fat and improving lipid profiles.
How is Mazdutide typically dosed in research?
Research protocols administer Mazdutide via subcutaneous injection once weekly, typically starting at 1.0mg to 1.5mg to build tolerance. Doses are titrated upwards every four weeks, with late-stage obesity trials pushing as high as 9.0mg per week.
What are the side effects of Mazdutide?
Gastrointestinal distress like nausea, vomiting, and diarrhea are common, especially during dose titrations. Subjects also consistently display an elevated resting heart rate due to the stimulatory nature of the glucagon receptor agonism.
How should Mazdutide be stored?
Lyophilized vials should be kept frozen at -20°C for long-term storage. Once reconstituted with bacteriostatic water, the solution must be refrigerated at 2-8°C and used within 28 days.
Ready to Purchase Mazdutide?
Get the highest quality Mazdutide from our recommended vendor with 99%+ purity guaranteed.
Buy at Peptide PalaceRelated Topics
Peptide Hormones and Their Functions
Peptide hormones are hydrophilic signaling molecules that bind cell surface receptors, triggering intracellular cascades via second messengers like cAMP and calcium.
Therapeutic Applications of Peptides
Therapeutic peptides occupy the pharmacological space between small molecules and biologics, offering high selectivity for protein-protein interactions with lower immunogenicity.
Safety & Reference
Related Peptides
Semaglutide
Semaglutide Acetate
Semaglutide is a GLP-1 receptor agonist that mimics the effects of the naturally occurring hormone GLP-1. It has gained significant attention for its powerful effects on appetite regulation and blood sugar control, leading to substantial weight loss in research subjects.
Learn MoreTirzepatide
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist, representing a new class of medications for metabolic conditions. It has shown remarkable efficacy in weight loss and glycemic control studies, often surpassing the results of single-receptor agonists.
Learn MoreCagrilintide
Cagrilintide (NN9838)
Just when we thought GLP-1 agonists had peaked, researchers started looking at amylin. Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk specifically to run alongside semaglutide. The combination, dubbed CagriSema in clinical trials, produces weight loss numbers that straight-up rival bariatric surgery. It attacks appetite from a completely different neurological angle than tirzepatide or semaglutide, making it the ultimate plateau-breaker for subjects who have stalled on standard therapies.
Learn MoreRetatrutide
Retatrutide (LY3437943)
Retatrutide is the heavyweight champ of the incretin world right now. Eli Lilly engineered this 39-amino-acid peptide to hit three different receptors at once: GLP-1, GIP, and Glucagon. While semaglutide targets one pathway and tirzepatide hits two, retatrutide's 'triple G' approach pushed clinical trial weight loss past the 24% mark in under a year. We haven't seen anything this potent before outside of bariatric surgery.
Learn More